🚀 VC round data is live in beta, check it out!
Harmony Biosciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Harmony Biosciences and similar public comparables like Sawai Group Holdings, Pharma Mar, Kodiak Sciences, Amylyx Pharmaceuticals and more.
Harmony Biosciences Overview
About Harmony Biosciences
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Founded
2017
HQ
Employees
293
Website
Sectors
Financials (LTM)
EV
$1B
Harmony Biosciences Financials
Harmony Biosciences reported last 12-month revenue of $896M and EBITDA of $258M.
In the same LTM period, Harmony Biosciences generated $692M in gross profit, $258M in EBITDA, and $168M in net income.
Revenue (LTM)
Harmony Biosciences P&L
In the most recent fiscal year, Harmony Biosciences reported revenue of $868M and EBITDA of $255M.
Harmony Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $896M | XXX | $868M | XXX | XXX | XXX |
| Gross Profit | $692M | XXX | $670M | XXX | XXX | XXX |
| Gross Margin | 77% | XXX | 77% | XXX | XXX | XXX |
| EBITDA | $258M | XXX | $255M | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 29% | XXX | XXX | XXX |
| EBIT Margin | 25% | XXX | 24% | XXX | XXX | XXX |
| Net Profit | $168M | XXX | $159M | XXX | XXX | XXX |
| Net Margin | 19% | XXX | 18% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Harmony Biosciences Stock Performance
Harmony Biosciences has current market cap of $2B, and enterprise value of $1B.
Market Cap Evolution
Harmony Biosciences' stock price is $28.90.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $2B | 0.0% | XXX | XXX | XXX | $2.76 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHarmony Biosciences Valuation Multiples
Harmony Biosciences trades at 1.3x EV/Revenue multiple, and 4.5x EV/EBITDA.
EV / Revenue (LTM)
Harmony Biosciences Financial Valuation Multiples
As of March 7, 2026, Harmony Biosciences has market cap of $2B and EV of $1B.
Equity research analysts estimate Harmony Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Harmony Biosciences has a P/E ratio of 9.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | 4.5x | XXX | 4.5x | XXX | XXX | XXX |
| EV/EBIT | 5.2x | XXX | 5.6x | XXX | XXX | XXX |
| EV/Gross Profit | 1.7x | XXX | 1.7x | XXX | XXX | XXX |
| P/E | 9.9x | XXX | 10.5x | XXX | XXX | XXX |
| EV/FCF | 3.5x | XXX | 3.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Harmony Biosciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Harmony Biosciences Margins & Growth Rates
Harmony Biosciences' revenue in the last 12 month grew by 17%.
Harmony Biosciences' revenue per employee in the last FY averaged $3.1M.
Harmony Biosciences' rule of 40 is 45% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Harmony Biosciences' rule of X is 70% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Harmony Biosciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 25% | XXX | 24% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 45% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 70% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $3.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 14% | XXX | 14% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 17% | XXX | 18% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 22% | XXX | 22% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 53% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Harmony Biosciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Sawai Group Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharma Mar | XXX | XXX | XXX | XXX | XXX | XXX |
| Kodiak Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Amylyx Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| AnaptysBio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Harmony Biosciences M&A Activity
Harmony Biosciences acquired XXX companies to date.
Last acquisition by Harmony Biosciences was on XXXXXXXX, XXXXX. Harmony Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Harmony Biosciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHarmony Biosciences Investment Activity
Harmony Biosciences invested in XXX companies to date.
Harmony Biosciences made its latest investment on XXXXXXXX, XXXXX. Harmony Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Harmony Biosciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Harmony Biosciences
| When was Harmony Biosciences founded? | Harmony Biosciences was founded in 2017. |
| Where is Harmony Biosciences headquartered? | Harmony Biosciences is headquartered in United States. |
| How many employees does Harmony Biosciences have? | As of today, Harmony Biosciences has over 293 employees. |
| Who is the CEO of Harmony Biosciences? | Harmony Biosciences' CEO is Jeffrey M. Dayno. |
| Is Harmony Biosciences publicly listed? | Yes, Harmony Biosciences is a public company listed on Nasdaq. |
| What is the stock symbol of Harmony Biosciences? | Harmony Biosciences trades under HRMY ticker. |
| When did Harmony Biosciences go public? | Harmony Biosciences went public in 2020. |
| Who are competitors of Harmony Biosciences? | Harmony Biosciences main competitors are Sawai Group Holdings, Pharma Mar, Kodiak Sciences, Amylyx Pharmaceuticals. |
| What is the current market cap of Harmony Biosciences? | Harmony Biosciences' current market cap is $2B. |
| What is the current revenue of Harmony Biosciences? | Harmony Biosciences' last 12 months revenue is $896M. |
| What is the current revenue growth of Harmony Biosciences? | Harmony Biosciences revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of Harmony Biosciences? | Current revenue multiple of Harmony Biosciences is 1.3x. |
| Is Harmony Biosciences profitable? | Yes, Harmony Biosciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Harmony Biosciences? | Harmony Biosciences' last 12 months EBITDA is $258M. |
| What is Harmony Biosciences' EBITDA margin? | Harmony Biosciences' last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Harmony Biosciences? | Current EBITDA multiple of Harmony Biosciences is 4.5x. |
| What is the current FCF of Harmony Biosciences? | Harmony Biosciences' last 12 months FCF is $332M. |
| What is Harmony Biosciences' FCF margin? | Harmony Biosciences' last 12 months FCF margin is 37%. |
| What is the current EV/FCF multiple of Harmony Biosciences? | Current FCF multiple of Harmony Biosciences is 3.5x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.